Aspen Pharmacare looking good at the price, say analysts
The pharmaceutical group expects Heps to rise more than a third in its 2022 half year, benefiting from lower finance costs
01 February 2022 - 12:17
UPDATED 01 February 2022 - 19:41
Shares of Aspen Pharmacare rose the most in a month after SA’s biggest pharmaceutical manufacturer said it expected headline profit to rise by more than a third in its 2022 half-year.
Headline earnings per share (Heps) for the six months to December will be 34%-38% higher than the prior comparative period, the group said in a trading update, sending its shares up as much as 6% in intraday trade. ..
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.